A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 6, 2012, Pages 227-234

  Suzuki, Hidenobu ^a   Inoue, Yuichi ^b   Gen, Keishi ^c  

^a Tanzawa Hospital   (Japan)

^b Shakomae Kokorono Clinic   (Japan)

^c Seimo Hospital   (Japan)

Author keywords

Efficacy; older patients with schizophrenia; risperidone long acting injection; safety

Indexed keywords

BIPERIDEN; DIAZEPAM; LONG ACTING DRUG; MAGNESIUM OXIDE; RISPERIDONE; SENNOSIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL PATIENT; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SUICIDE ATTEMPT; TARDIVE DYSKINESIA;

EID: 84997907648     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125312457585     Document Type: Article

References (18)

1. Baggaley M. (2008) Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 23: 201–209.
2. Chue P. Eerdekens M. Augustyns I. Barnard L. Molcan P. Eriksson L. et al. (2005) Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15: 111–117.
3. Dossenbach M. DyachKova Y. Pirildar S. Anders M. Khalil A. Araszkiewicz A. et al. (2006) Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia 12-month results from the Inter Continental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 21: 251–258.
4. Haupt D. (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuro-Psychopharmacol 16(Suppl. 3): 149–155.
5. Inada T. (1996) Evaluation and diagnosis of drug-induced extrapyramidal symptoms. In: Yagi G. (ed.), Commentary on the DIEPSS and Guide to its Usage. Tokyo: Seiwa Publishers, pp. 11–60 (in Japanese).
6. Inada T. Yagi G. Gardos G. (1996) Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). Abstracts of 20th Collegium Internationale Neuropsycho-Pharmacologicum, Melbourne, Australia, pp. 23–27.
7. Inagaki A. Inada T. (2010) Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidone long-acting injection. Jpn Clin Psychopharmacol 13: 1349–1353 (in Japanese).
8. Kamijima K. Ishigooka J. Komeda Y. (2009) Long term treatment with risperidone long-acting injectable in patients with schizophrenia. Jpn J Clin Psychopharmacol 12: 1223–1244 (in Japanese).
9. Kane J. Eerdenkens M. Lindenmayer J. Keith S. Lesem M. Karcher M. (2003) Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160: 1125–1132.
10. Keith S. Kane J. (2003) Partial compliance and patient consequences in schizophrenia our patients can do better. J Clin Psychiatry 64: 1308–1315.
11. Kissling W. Glue P. Medori R. Simpson S. (2007) Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol 22: 505–513.
12. Lasser R. Bossie C. Zhu Y. Gharabawi G. Eerdekens M. Davidson M. (2004) Efficacy and safety of long-acting risperidone in elderly with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 19: 898–905.
13. Nesvag R. Hendset M. Refsum H. Tanum L. (2006) Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 114: 21–26.
14. Newcomer J. Haupt D. (2006) The metabolic effects of antipsychotic medication. Can J Psychiatry 51: 480–491.
15. Schmauss M. Sacchetti E. Kahn J. Rossella M. (2007) Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 22: 85–92.
16. Taylor D. Fischetti C. Sparshatt A. Thomas A. Bishara D. Cornelius V. (2009a) Risperidone long-acting injection: a prospective 3 year analysis of its use in clinical practice. J Clin Psychiatry 70: 196–200.
17. Taylor D. Fischetti C. Sparshatt A. Thomas A. Bishara D. Cornelius V. (2009b) Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use. Acta Psychiatr Scand 120: 97–101.
18. Tschoner A. Engl J. Rettenbacher M. Edlinger M. Kaser S. Tatarczyk T. et al. (2009) Effects of six second generation antipsychotics on body weight and metabolism-risk assessment and results from a prospective study. Pharmacopsychiatry 42: 29–34.